mCRPC (Metastatic Castration-resistant Prostate Cancer) Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting mcrpc (metastatic castration-resistant prostate cancer) clinical trials across 6 countries. Studies span Phase 1, Phase 2, Not Applicable. Top locations include Omaha, Nebraska, United States, Miami, Florida, United States, Detroit, Michigan, United States. Updated daily from ClinicalTrials.gov.


mCRPC (Metastatic Castration-resistant Prostate Cancer) Trials at a Glance

11 actively recruiting trials for mcrpc (metastatic castration-resistant prostate cancer) are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Omaha, Miami, and Detroit. Lead sponsors running mcrpc (metastatic castration-resistant prostate cancer) studies include Aktis Oncology, Inc., Celcuity Inc, and Acerand Therapeutics (Hong Kong) Limited.

Browse mcrpc (metastatic castration-resistant prostate cancer) trials by phase

Treatments under study

About mCRPC (Metastatic Castration-resistant Prostate Cancer) Clinical Trials

Looking for clinical trials for mCRPC (Metastatic Castration-resistant Prostate Cancer)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new mCRPC (Metastatic Castration-resistant Prostate Cancer) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about mCRPC (Metastatic Castration-resistant Prostate Cancer) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled5 locationsNCT06844383
Recruiting
Phase 1

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Breast CancerCervical CancerColon Cancer+4 more
Orano Med Theranostics, SAS48 enrolled8 locationsNCT05283330
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Pathos AI, Inc.120 enrolled18 locationsNCT06785636
Recruiting
Phase 1

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Castration Resistant Metastatic Prostate Cancer+2 more
Aktis Oncology, Inc.138 enrolled2 locationsNCT07581184
Recruiting
Phase 2

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University66 enrolled3 locationsNCT07451795
Recruiting
Phase 1Phase 2

A Study of MHB048C in Patients With Advanced Solid Tumors

Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting
Phase 1Phase 2

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 1

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)+2 more
K36 Therapeutics, Inc.144 enrolled13 locationsNCT07103018
Recruiting
Not Applicable

Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity

mCRPC (Metastatic Castration-resistant Prostate Cancer)
Frederic Pouliot45 enrolled1 locationNCT07302763
Recruiting
Phase 1Phase 2

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

mCRPC (Metastatic Castration-resistant Prostate Cancer)Metastatic Castrate Resistant Prostate Cancer
Evopoint Biosciences Inc.307 enrolled2 locationsNCT06702995